Thomas Willigenburg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thomas Willigenburg has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
Jochem R.N. van der Voort van Zyp
8 shared publicationsJan J.W. Lagendijk
University Medical Center Utrecht, Department of Radiation Oncology, 3508 GA Utrecht, The Netherlands
7 shared publicationsHans C.J. de Boer
University Medical Centre Utrecht, Department of Radiation Oncology, 3508 GA Utrecht, The Netherlands
5 shared publicationsBas W. Raaymakers
University Medical Center Utrecht, Department of Radiation Oncology, 3508 GA Utrecht, The Netherlands
4 shared publicationsCornel Zachiu
University Medical Center Utrecht, Department of Radiation Oncology, 3508 GA Utrecht, The Netherlands
3 shared publicationsDaan M. de Muinck Keizer
Department of Radiation Oncology, University Medical Center Utrecht, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 2 August 2026
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 40
Deep learning-enhanced image registration for accelerating daily adaptive magnetic resonance imaging-guided prostate radiotherapy
- 2 August 2026
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 40
Open AccessDeep learning-enhanced image registration for accelerating daily adaptive magnetic resonance imaging-guided prostate radiotherapy
- Open Access
- 4 July 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 221, 111642
How to focal boost in prostate cancer radiotherapy: ESTRO clinical practice consensus recommendations
- 4 July 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 221, 111642
Open AccessHow to focal boost in prostate cancer radiotherapy: ESTRO clinical practice consensus recommendations
- 24 July 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 182, S784-S785
OC-0937 Small planning margins by intrafraction re-planning on a MR-linac in 65 prostate ca. patients
- 24 July 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 182, S784-S785
OC-0937 Small planning margins by intrafraction re-planning on a MR-linac in 65 prostate ca. patients
- 24 July 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 182, S2111-S2112
PO-2347 Bladder wall dose in PCa patients treated with stereotactic, daily adaptive MR-guided radiotherapy
- 24 July 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 182, S2111-S2112
PO-2347 Bladder wall dose in PCa patients treated with stereotactic, daily adaptive MR-guided radiotherapy
- Open Access
- 14 September 2022
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 176, 25-30
Clinical application of a sub-fractionation workflow for intrafraction re-planning during prostate radiotherapy treatment on a 1.5 Tesla MR-Linac: A practical method to mitigate intrafraction motion
- 14 September 2022
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 176, 25-30
Open AccessClinical application of a sub-fractionation workflow for intrafraction re-planning during prostate radiotherapy treatment on a 1.5 Tesla MR-Linac: A practical method to mitigate intrafraction motion
- Open Access
- 21 July 2022
- Published by Springer Nature in World Journal of Urology
- Vol. 40 (9) , 2205-2212
The first patient-reported outcomes from the Utrecht Prostate Cohort (UPC): the first platform facilitating ‘trials within cohorts’ (TwiCs) for the evaluation of interventions for prostate cancer
Purpose: To describe the development and first outcomes of the Utrecht Prostate Cohort (UPC): the first ‘trials within cohorts’ (TwiCs) platform for prostate cancer (PCa). Methods: All non-metastasized, histologically proven PCa patients who are planned to receive standard of care are eligible for inclusion in UPC. Patients provide informed consent for the collection of clinical and technical patient data, physician-reported outcomes, and patient-reported outcomes (PROs) up to 10 years post-treatment. Additionally, patients may provide broad consent for future randomization for experimental-intervention trials (TwiCs). Changes in PROs (EPIC-26 questionnaire domains) of the participants who received standard of care were analyzed using Wilcoxon signed-rank tests. Results: In two years, 626 patients were enrolled, 503 (80.4%) of whom provided broad consent for future randomization. Among these, 293 (46.8%) patients underwent magnetic resonance-guided adaptive radiotherapy (MRgRT), 116 (18.5%) CT-guided external beam radiation therapy (EBRT), 109 (17.4%) robot-assisted radical prostatectomy (RARP), and 65 (10.4%) patients opted for active surveillance. Patients treated with MRgRT and CT-guided EBRT showed a transient but significant decline in urinary irritative/obstructive and bowel domain scores at 1-month follow-up. RARP patients showed a significant deterioration of urinary incontinence domain scores between baseline and all follow-up moments and significant improvement of urinary irritative/obstructive domain scores between baseline and 9- and 12-month follow-up. All radical treatment groups showed a significant decline in sexual domain scores during follow-up. Active surveillance patients showed no significant deterioration over time in all domains. Conclusion: The first results from the UPC study show distinct differences in PROs between treatment options for PCa. Registration No.: NCT04228211.
- 21 July 2022
- Published by Springer Nature in World Journal of Urology
- Vol. 40 (9) , 2205-2212
Open AccessThe first patient-reported outcomes from the Utrecht Prostate Cohort (UPC): the first platform facilitating ‘trials within cohorts’ (TwiCs) for the evaluation of interventions for prostate cancer
Purpose: To describe the development and first outcomes of the Utrecht Prostate Cohort (UPC): the first ‘trials within cohorts’ (TwiCs) platform for prostate cancer (PCa). Methods: All non-metastasized, histologically proven PCa patients who are planned to receive standard of care are eligible for inclusion in UPC. Patients provide informed consent for the collection of clinical and technical patient data, physician-reported outcomes, and patient-reported outcomes (PROs) up to 10 years post-treatment. Additionally, patients may provide broad consent for future randomization for experimental-intervention trials (TwiCs). Changes in PROs (EPIC-26 questionnaire domains) of the participants who received standard of care were analyzed using Wilcoxon signed-rank tests. Results: In two years, 626 patients were enrolled, 503 (80.4%) of whom provided broad consent for future randomization. Among these, 293 (46.8%) patients underwent magnetic resonance-guided adaptive radiotherapy (MRgRT), 116 (18.5%) CT-guided external beam radiation therapy (EBRT), 109 (17.4%) robot-assisted radical prostatectomy (RARP), and 65 (10.4%) patients opted for active surveillance. Patients treated with MRgRT and CT-guided EBRT showed a transient but significant decline in urinary irritative/obstructive and bowel domain scores at 1-month follow-up. RARP patients showed a significant deterioration of urinary incontinence domain scores between baseline and all follow-up moments and significant improvement of urinary irritative/obstructive domain scores between baseline and 9- and 12-month follow-up. All radical treatment groups showed a significant decline in sexual domain scores during follow-up. Active surveillance patients showed no significant deterioration over time in all domains. Conclusion: The first results from the UPC study show distinct differences in PROs between treatment options for PCa. Registration No.: NCT04228211.
- Open Access
- 28 April 2022
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 171, 182-188
Accumulated bladder wall dose is correlated with patient-reported acute urinary toxicity in prostate cancer patients treated with stereotactic, daily adaptive MR-guided radiotherapy
- 28 April 2022
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 171, 182-188
Open AccessAccumulated bladder wall dose is correlated with patient-reported acute urinary toxicity in prostate cancer patients treated with stereotactic, daily adaptive MR-guided radiotherapy
- Open Access
- 17 February 2022
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 21, 62-65
Fast and accurate deformable contour propagation for intra-fraction adaptive magnetic resonance-guided prostate radiotherapy
- 17 February 2022
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 21, 62-65
Open AccessFast and accurate deformable contour propagation for intra-fraction adaptive magnetic resonance-guided prostate radiotherapy
- Open Access
- 1 September 2021
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 30, 7-14
Development and internal validation of multivariable prediction models for biochemical failure after MRI-guided focal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer
- 1 September 2021
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 30, 7-14
Open AccessDevelopment and internal validation of multivariable prediction models for biochemical failure after MRI-guided focal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer
- Open Access
- 1 March 2021
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 27, 50-56
Evaluation of daily online contour adaptation by radiation therapists for prostate cancer treatment on an MRI-guided linear accelerator
- 1 March 2021
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 27, 50-56
Open AccessEvaluation of daily online contour adaptation by radiation therapists for prostate cancer treatment on an MRI-guided linear accelerator